Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 12
Submit an article Journal homepage
24
Views
0
CrossRef citations to date
0
Altmetric
Review

Patents on antifungal compounds effective against Candida species: 1999 – 2002

Constantine G Haidaris Department of Microbiology & Immunology and Center for Oral Biology, University of Rochester School of Medicine and Dentistry, Box 672, 601 Elmwood Ave., Rochester, NY 14642, USA. [email protected]
Pages 1849-1866 | Published online: 02 Mar 2005

Bibliography

  • ODDS FC (Ed.): Candida and candidosis (2nd ed). Bailliere Tindall, London, UK (1988).
  • •An encyclopaedic compendium of the Candida literature up to 1988 that remains a useful reference.
  • WENZEL RP: Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. (1995) 20 (6):1531–1534.
  • •An authoritative account of Candida epidemiology.
  • EDMOND MB, WALLACE SE, MCCLISH DK, PFALLER MA, JONES RN, WENZEL RP: Nosocomial bloodstream infections in United States hospitals: a 3-year analysis. Clin. Infect. Dis. (1999) 29(2):239–244.
  • ODDS FC: Candida species and virulence. ASM News (1994) 60:313–318.
  • WALSH TJ, GONZALEZ C, ROILIDES E et al: Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin. Infect. Dis. (1995) 20(4):900–906.
  • MARR KA, SEIDEL K, WHITE TC, BOWDEN RA: Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. Infect. Dis. (2000) 181(1):309–316.
  • PFALLER MA, JONES RN, MESSER SA, EDMOND MB, WENZEL RP: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. (1998) Diag. Microbiol Infect. Dis. 30(2):121–129.
  • •A thorough account of the emergence of non-albicans Candida species as significant pathogens.
  • REX JH, PFALLER MA, WALSH TJ et at.: Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol Rev (2001) 14(4):643–658.
  • REX JH, PFALLER MA: Has antifungal susceptibility testing come of age? Clin. Infect. Dis. (2002) 35(8):982–989.
  • •Current opinion on the relationship between in vitro susceptibility testing and clinical efficacy of antifungals.
  • SABO JA, ABDEL-RAHMAN SM: Voriconazole: a new triazole antifungal. Ann. Pharinacother. (2000) 34(9):1032–1043.
  • STEINBACH WJ, PERFECT JR: Newer antifungal therapy for emerging fungal pathogens. Int. J. kifrt. Dis. (2003) 7(1):5–20.
  • DIGIORGIO D, CAMONI L, MARCHIAFAVA C, BALLIO A: Biological activities of pseudomycin A, a lipodepsinonapeptide from Pseudomonas syringiae MSU-16H. Phytocheinistry (1997) 45(41385–1391.
  • CAPA L, MENDOZA A, LAVANDERA JL, GOMEZ DE LAS HERAS F, GARCIA-BUSTOS JF: Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob. Agents Cheinother. (1998) 42(102694–2699.
  • YU XY, HILL JM, YU Get al.: A series of quinoline analogues as potent inhibitors of C. albicansprolyl tRNA synthetase. Bioorg. Med. Chem. Lett. (2001) 11(4):541–544.
  • VARGAS SL, PATRICK CC, AYERS GD, HUGHES WT: Modulating effect of dietary carbohydrate supplementation on Candida albicans colonization and invasion in a neutropenic mouse model. Infect. Immun. (1993) 61(2):619–626.
  • CALDERONE RA (ed.): Candida and Candidiasis. ASM Press, Washington, DC, USA (2002)
  • ••The most up-to-date resource forinformation on all aspects of Candida biology, pathogenesis and clinically relevant aspects of candidiasis.
  • HORNBY JM, JENSEN EC, LISEC AD et al.: Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl. Environ. Microbic] (2001) 67(7):2982–2992.
  • ••The first report of a mediator of quorumsensing in Candida.
  • RAMAGE G, SAVILLE SP, WICKES BL, LOPEZ-RIBOT JL: Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ. Microbiol (2002) 68(11):5459–5463.
  • MATTHEWS R, HODGETTS S, BURNIE J: Preliminary assessment of a human recombinant antibody fragment to Hsp90 in murine invasive candidiasis. J. Infect. Dis. (1995) 171(6):1668–1671.
  • DEVASAHAYAM G, CHATURVEDI V, HANES SD: The Essl prolyl isomerase is required for growth and morphogenetic switching in Candida albicans. Genetics. (2002) 160(0:37–48.
  • CALERA JA, ZHAO XJ, CALDERONE R: Defective hyphal development and avirulence caused by a deletion of the SSK1 response regulator gene in Candida albicans. Infect. Inman. (2000) 68(2):518–525.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.